A phase II trial of SU5416 (NSC 696819) [semaxanib] in patients with advanced or recurrent squamous cell carcinoma of the head and neck
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2010
At a glance
- Drugs Semaxanib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 17 Dec 2009 Actual end date (Jan 2003) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2005 New trial record.